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Objective : Anti-malaria drugs may modulate tumor resistance to chemotherapeutic agents, but it has not been proven
effective in the treatment of malignant gliomas. The aim of this study was to determine whether adequate pre-clinical data
on co-administration of chemotherapeutic agents with anti-malaria drugs on malignant cell lines could be obtained that
would warrant its further potential consideration for use in a clinical trial for malignant gliomas.
Methods : Two malignant glioma cell lines (U87MG, T98G) were treated with chemotherapeutic agents alone or with anti-
malaria drugs. Cells were incubated with drugs for 4 days. Following the 4-day incubation, drug sensitivity assays were
performed using 3-(4,5-dimethyl-2-thiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT) assay following optimization of
experimental conditions for each cell lines and cell viability was calculated. 
Results : In all of four chemotherapeutic agents(doxorubicin, vincrisitne, nimustine, and cisplatin), the cell viability was found
to be markedly decreased when hydroxychloroquine was co-administered on both U87MG and T98G cell lines. The two way
analysis of variance(ANOVA) yielded a statistically significant two-sided p-value of 0.0033(doxorubicin), 0.0005(vincrisitne),
0.0007(nimustine), and 0.0003(cisplatin) on U87MG cell lines and 0.0006(doxorubicin), 0.0421(vincrisitne), 0.0317(nimustine),
and 0.0001(cisplatin) on T98G cell lines, respectively. However, treatment with chloroquine and primaquine did not induce a
decrease in cell viability on both U87MG and T98G cell lines.
Conclusion : Our data support further consideration of the use of hydroxychloroquine prior to systemic chemotherapy to
maximize its tumoricidal effect for patients with malignant gliomas. 
KEY WORDS : Anti-malarial drugs·Hydroxychloroquine·Chemotherapy·Multidrug resistance·
Malignant glioma.
Introduction
Many ongoing studies have explored new therapeuticapproaches to improve the outcome for patients with
malignant gliomas in the recent years. Even though, systemic
chemotherapy is considered as an principal adjuvant treatment
to surgical resection in the management of malignant gliomas,
intrinsic or induced drug resistance is thought to be one of
the obstacles in chemotherapy2,9,26). 
The mechanisms underlying this drug resistance have been
studied, leading to the characterization of genes capable of
conferring resistance to chemotherapeutic drugs. Among
these genes, the multi-drug resistance type 1 (mdr1) gene has
been of particular interest because its over-expression can
lead to resistance to cytotoxic drugs such as anthracyclines,
vinca alkaloids, and epipodophyllotoxins by the P-glycoprotein
(P-gp)1,3,5,7-10,14,16,21,22-24,32). Increased levels of P-gp are common
in cancer cells. Moreover, levels of the glycoprotein can be
increased after chemotherapy, when the tumor becomes
refractory to treatment. P-gp encoded by mdr1 gene functions
as membrane-bound transporters, mediating ATP-dependent
efflux of various structurally and functionally unrelated
substrates from the cell10,24,25). Some chemosensitizing agents
have been shown to overcome mdr1 gene phenotype in expe-
riments. Recently, anti-malarial drugs have raised considerable
interest because of its anti-carcinogenic properties and its
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ability to inhibit tumor development and virus replication31).
Lagneaux and colleagues reported that hydroxychloroquine
induced an early apoptosis in B-chronic lymphocytic leukemia
cells18). Inaba et al reported that an antimalarial drug, especially
quinacrine, exhibited therapeutic synergism in combination
with vincristine in resistant leukemia-bearing mice13). In the
literature, however, few reports are available pertaining to
the experimental or clinical trial of chemosensitizing agents
prior to systemic chemotherapy in malignant gliomas. 
The aim of this study was to determine whether adequate
pre-clinical data on co-administration of chemotherapeutic
agents with anti-malaria drugs could be obtained that would
warrant its further consideration for use in a clinical trial for
malignant gliomas.
Materials and Methods
Cell lines
Human glioblastoma cell lines, U87MG and T98G, were
obtained from the American Type Culture Collection (Ma-
nassas, VA). All cells were grown as monolayers in Dulbecco’s
modified Eagle’s medium (Gibco/BRL, Gaithersburg, MD)
supplemented with 10% fetal bovine serum(FBS) (ICN
Biomedicals, Inc., Costa Mesa, CA), penicillin, and strepto-
mycin at 37。C in a humidified atmosphere with 5% CO2.
Drugs
All drugs were obtained from commercial sources : doxo-
rubicin(adriamycin; Farmitalia Carlo Erba Ltd, Italy), vinc-
risitne(oncovin; Eli Lilly, USA), nimustine(ACNU; Sankyo
Co., LTD, Japan), cisplatin(platinol; Bristol-Myers Squibb,
USA), hydroxychloroquine(oxiklorin; Orion Pharmaceutica,
Finland), chloroquine(aralen; Sanofi Winthrop, USA), pri-
maquine(primaquine; Sanofi Winthrop, USA). The chemo-
therapeutic agents were tested over the following concentration
ranges : doxorubicin 0.01, 0.1, 1, and 10㎍/ml; vincristine
0.005, 0.05, 0.5, and 5㎍/ml; nimustine 0.005, 0.05, 0.5,
and 5㎍/ml; cisplatin 0.005, 0.05, 0.5, and 5㎍/ml. The
anti-malaria drugs were employed with the following concen-
tration ranges : hydroxychloroquine 15㎍/ml and 30㎍/ml;
chloroquine 20㎍/ml and 40㎍/ml; primaquine 1.5㎍/ml
and 3㎍/ml. All drugs were dissolved or diluted with phosphate
buffered saline(PBS) and prepared immediately prior to use.  
3-(4,5-dimethyl-2-thiazol-2-yl) 2,5-diphenyltetrazolium
bromide (MTT) assay
Single cell suspensions were obtained by pipet disaggrega-
tion of the floating cell line or by trypsinization of monolayer
cultures, and cell counts were performed using a hemocytometer.
The assay was dependent on the cellular reduction of MTT
(Sigma Chemical Co., St.Louis, MO) by the mitochondrial
dehydrogenase of viable cells to a blue formazan product
which can be measured spectrophotometrically. Cells were
plated in 180㎕ medium at the appropriate seeding density
into 96 well microtiter plates after preliminary cell growth
studies using MTT assay so that untreated cells were in
exponential growth phase at the time of initial harvest and
at the end of the 4-day incubation. Cell number per micro-
titer well was proportional to the absorbance of the solubilized
formazan. To each well 20㎕ of 10x drug in PBS was added,
with PBS added to control wells. Cells were incubated with
or without drug for 4days, allowing sufficient time for cell
replication, drug induced cell death, and loss of enzyme
activity, which generate the formazan product. Following
the 4day incubation, 0.1mg (50㎕ of 2mg/ml) of MTT
solution was added to each well, and the plates incubated at
37。C for 4h. The microtiter plates were centrifuged at 500g
for 5min, 200㎕ supernatant removed from plates leaving
about 30㎕ residual medium in each well. Care had to be
taken not to disturb the formazan crystals at the bottom of
the wells. MTT formazan crystals were resolubilized by
adding 130㎕ 100% dimethylsulfoxide (DMSO) to each
well. Plates were then placed on a shaker for 10min. The plates
were read immediately at 540nm on a scanning multiwell
ELISA automatic spectrophotometer recorder (Behring ELISA
Processor II, Germany). Cell survival(viability) was calculated
by the following formula :
% viability = 100×
Average absorbance of tested group-baseline absorbance
Average absorbance of control group-baseline absorbance
Data points in Fig. 1, 2, and 3 represent cell survival 4days
after plating and drug exposure measured by the MTT assay
for doxorubicin, vincrisitne, nimustine, and cisplatin for 3
different anti-malaria drugs on 2 different malignant glioma
cell lines.
Statistical analysis
Cell viability between anti-malaria drugs-treated and control
cells (chemotherapeutic agents only) was analyzed using the
two way analysis of variance (ANOVA). A probability value
of less than 0.05 was considered significant. All statistical
analyses were performed with commercially available software
(SAS, version 6.12, SAS Inc., Cary, NC).
Results
Effects of hydroxychloroquine co-administered with
chemotherapeutic agents
To evaluate the effects of hydroxychloroquine co-administered
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with chemotherapeutic agents, hydroxychloroquine-treated
and control cells(chemotherapeutic agents only) were analyzed
for cell survival. Treatment with hydroxychloroquine was
found to cause cell viability to decrease significantly as the
concentration of hydroxychloroquine increased on both
U87MG and T98G cell line. (Fig. 1A,B,C,D) shows these
characteristic changes for hydroxychloroquine co-administered
with chemotherapeutic agents in cell survival. 
In all of four chemotherapeutic agents(doxorubicin, vinc-
risitne, nimustine, and cisplatin), cell viability was found to
be markedly decreased. The two way ANOVA yielded a
two-sided p-value of 0.0033(doxorubicin), 0.0005(vincrisitne),
0.0007(nimustine), and 0.0003(cisplatin) on U87MG cell
line, respectively, which indicated that the effect of hydro-
xychloroquine co-administered with chemotherapeutic agents
was statistically significant.
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Fig. 1. Graph showing the effect of treatment with hydroxychloroquine. A~D, changes for hydroxychloroquine co-administered with
chemotherapeutic agents on U87MG cell lines. E~F, changes for hydroxychloroquine co-administered with chemotherapeutic agents on
T98G cell lines. In all of four chemotherapeutic agents(doxorubicin, vincrisitne, nimustine, and cisplatin), cell viability was found to markedly
decrease. The two way ANOVA yielded a two-sided p-value of 0.0033(doxorubicin), 0.0005(vincrisitne), 0.0007(nimustine), and 0.0003(cisplatin)
on U87MG cell lines and 0.0006(doxorubicin), 0.0421(vincrisitne), 0.0317(nimustine), and 0.0001(cisplatin) on T98G cell lines, respectively. ADR,
doxorubicin; VIN, vincristine; ACNU, nimustine; DDP, cisplatin; HCQ, hydroxychloroquine.
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To determine if similar effect occurred, we used a T98G
cell line. (Fig. 1E, F, G,H) also shows similar characteristic
changes in cell survival. In control cells (chemotherapeutic
agents only), there was a high cell viability, whereas treatment
with hydroxychloroquine decreased the cell viability. The two
way ANOVA yielded a statistically significant p-value of
0.0006(doxorubicin), 0.0421(vincrisitne), 0.0317(nimustine),
and 0.0001(cisplatin), respectively.
The effect of chemotherapeutic agents followed a concen-
tration-dependent pattern, but the cell viability was markedly
diminished at its lowest level of each anti-cancer drug on
both U87MG and T98G cell line. 
Effects of chloroquine and primaquine co-administered
with chemotherapeutic agents 
Experiments were also performed to determine whether
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Fig. 2.Graph showing the effect of treatment with chloroquine. A~D, changes for chloroquine co-administered with chemotherapeutic agents
on U87MG cell lines. E~F, changes for chloroquine co-administered with chemotherapeutic agents on T98G cell. Chloroquine was not found
to decrease the cell viability on glioma cell lines. The two way ANOVA showed no statistical significance. In chloroquine-treated cells with
doxorubicin only, there was a trend approaching statistical significance(p=0.0614). ADR, doxorubicin; VIN, vincristine; ACNU, nimustine; DDP,
cisplatin; CQ, chloroquine.
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treatment with other anti-malaria drugs(chloroquine, pri-
maquine) would have a similar effect on both U87MG and
T98G cell line. 
Unlike the effect of treatment with hydroxychloroquine,
chloroquine was not found to decrease the cell viability on
glioma cell line. The two way ANOVA showed no statistical
significance(Fig. 2). In chloroquine-treated cells with doxoru-
bicin only(Fig. 2A), there was a trend approaching statistical
significance(p=0.0614). Results of cell viability for chloroquine
are shown in Fig. 2.
Primaquine was also used to compare the cell viability be-
tween anti-malaria drugs-treated and control cells. Treatment
with primaquine showed a similar effect to chloroquine on
both U87MG and T98G cell line. The two way ANOVA
showed no statistical significance(Fig. 3). In primaquine-
treated cells with doxorubicin on both U87MG and T98G
Fig. 3.Graph showing the effect of treatment with primaquine. A~D, changes for primaquine co-administered with chemotherapeutic agents
on U87MG cell lines. E~F, changes for primaquine co-administered with chemotherapeutic agents on T98G cell. Treatment with primaquine
showed a similar effect to chloroquine on both U87MG and T98G cell line. The two way analysis of variance showed no statistical significance. In
primaquine-treated cells with doxorubicin on both U87MG and T98G cell, there was a trend approaching statistical significance(p=0.0531,
0.0587, respectively). ADR, doxorubicin; VIN, vincristine; ACNU, nimustine; DDP, cisplatin; PQ, primaquine.
Vi
ab
ilit
y(
%
)
VIN+PQ
VIN ONLY
p=0.0715
PQ1.5+VIN
PQ3+VIN
B
140
120
100
80
60
40
20
0
Control VIN 0.005 VIN 0.05 VIN 0.5 VIN 5
Vi
ab
ilit
y(
%
)
DDP+PQ
DDP ONLY
p=0.2106
PQ1.5+DDP 
PQ3+DDP 
140
120
100
80
60
40
20
0
Control DDP 0.005 DDP 0.05 DDP 0.5 DDP 5
Vi
ab
ilit
y(
%
)
ADR+PQ
ADR ONLY
p=0.0587
PQ1.5+ADR 
PQ3+ADR 
140
120
100
80
60
40
20
0
Control ADR 0.01 ADR 0.1 ADR 1 ADR 10  
D
Vi
ab
ilit
y(
%
)
VIN+PQ
VIN ONLY
p=0.5997
PQ1.5+VIN
PQ3+VIN 
120
100
80
60
40
20
0
Control VIN 0.005 VIN 0.05 VIN 0.5 VIN 5
FE
Vi
ab
ilit
y(
%
)
ACNU+PQ
ACNU ONLY
p=0.0621
PQ1.5+ACNU
PQ3+ACNU
140
120
100
80
60
40
20
0
Control ACNU 0.005 ACNU 0.05 ACNU 0.5 ACNU 5
G
Vi
ab
ilit
y(
%
)
DDP+PQ
DDP ONLY
p=0.2897
PQ1.5+DDP 
PQ3+DDP 
140
120
100
80
60
40
20
0
Control DDP 0.005 DDP 0.05 DDP 0.5 DDP 5
H
Vi
ab
ilit
y(
%
)
ADR+PQ
ADR ONLY
p=0.0531
PQ1.5+ADR 
PQ3+ADR 
140
120
100
80
60
40
20
0
Control ADR 0.01 ADR 0.1 ADR 1 ADR 10
A
Vi
ab
ilit
y(
%
)
ACNU+PQ
ACNU ONLY
p=0.0837
PQ1.5+ACNU
PQ3+ACNU 
140
120
100
80
60
40
20
0
Control ACNU 0.005 ACNU 0.05 ACNU 0.5 ACNU 5
C
J Korean Neurosurg Soc  38｜July 2005
cell lines(Fig. 3A, E), there was a trend approaching statistical
significance(p=0.0531, 0.0587, respectively). Results of cell
viability for primaquine are shown in Fig. 3.
Discussion
This study paradigm has demonstrated that hydroxych-loroquine induced a dramatic tumoricidal effect of
anti-cancer drugs on malignant glioma cell lines in vitro.
Treatment with hydroxychloroquine produced a marked
decrease in glioma cell viability. The mechanisms in this
model are not known but, multi-drug resistance likely plays
a significant role3,7-10,14,19-21,23-25).
Biedler and colleagues first described the phenomenon of
in vitro multi-drug resistance in the 1970s5). Cells selected
for resistance to one drug demonstrated cross resistance to
other structurally and functionally unrelated compounds.
The drugs that constitute the multi-drug resistance include
the anthracyclines, the vinca alkaloids, and the epipodophyl-
lotoxins. The multi-drug resistance phenotype is due apparently
to an important energy-dependent reduction in the intracel-
lular accumulation of cytotoxic drugs in resistant cells, caused
by an outward efflux10). The resistant cell lines overexpress a
transmembrane glycoprotein (P-glycoprotein, P-gp), which
is encoded by the mdr1 gene in human cells. It is commonly
found in carcinomas of the kidney, liver, adrenal glands, and
colon, and it is presumed that the increased resistance of these
carcinomas to cytostatic treatment is due to the expression
of P-gp28). In normal tissue the highest P-gp levels are found
in the adrenal glands, capillary endothelium of the brain, and
the kidney11). The high degree of chemoresistance in colorectal
carcinoma is well known in the oncological community17).
Veneroni and colleagues reported that a strong P-gp expres-
sion might serve as a negative prognostic marker for the
responsiveness of breast cancer to chemotherapy30). Dietz-
mann et al. demonstrated a positive correlation between the
fraction of P-gp-positive cells stained with the monoclonal
antibody JSB1 and tumor grading in glioma6). 
Several drugs affected by mdr1 gene have made it an attr-
active candidate to explain the phenomenon of multi-drug
resistance, whereby a tumor becomes refractory to drugs to
which it was never exposed. Some chemosensitizing agents
have been shown to overcome mdr1 phenotype in experi-
ments. Among them were calcium channel blockers such as
verapamil and quinine, calmodulin inhibitors such as phe-
nothiazines, the triparanol analogs tamoxifen, and cyclos-
porine21,25,29). These compounds also act mainly through
inhibition of the drug pumping by P-gp. Clinical studies of
such chemosensitizing agents given in combination with ch-
emotherapy have been performed in patients with hematologic
malignancies or solid tumors25). Many of these studies attem-
pted to achieve plasma concentration of these agents. However,
the significance of the plasma concentration remains unclear,
because we have virtually no knowledge of the concentrations of
these chemosensitizing agents and anti-cancer drugs in tumors.
Recently, anti-malaria drugs have raised considerable interest
because of its anti-carcinogenic properties and its ability to
inhibit virus replication and tumor development31). Lagneaux
and colleagues reported that hydroxychloroquine induced
an early induction of apoptosis in B-chronic lymphocytic
leukemia cells18). In the literature, few reports are available
pertaining to the effect of treatment with anti-malarial drugs
prior to chemotherapy.
A significant finding from our experiment was that treat-
ment with hydroxychloroquine caused the cell viability of
malignant glioma to decrease significantly as their concent-
ration increased. The effect of chemosensitizing agents on
tumor cells has been postulated to result from impairing the
pumping function of P-gp. The presumed mechanism in
our model is to bind P-gp and competitively interact with
chemotherapeutic agents-binding site of P-gp. As a result,
anti-malria drugs enhance the intracellular concentration of
cytotoxic drugs. However, other mechanisms for reversal of
multi-drug resistance cannot be excluded. For instance, it was
reported that promoting a redistribution of the chemothe-
rapeutic agent within the resistant cell allowed the drug to
reach its targets4). Also, the level of the protein kinase C
responsible for the phosphorylation of P-gp and mdr1 gene
expression could constitute a mechanism for multi-drug
resistance reversal not interfering with drug binding to P-
gp12,27). Additional mechanism of in vitro multi-drug resis-
tance distinct from P-gp expression has also been reported.
Altered activity and expression of the enzyme topoisomerase
II has been shown to produce resistance to the anthracyclines
and the epipodophyllotoxins15). Interestingly, however, unlike
the effect of treatment with hydroxychloroquine, chloroquine
and primaquine were not found to decrease the cell viability
on glioma cell lines in our study even though they were
classified into the same anti-malaria drugs. It remains unclear
by which reason chloroquine and primaquine don’t induce
a significant decrease in glioma cell viability.
Another finding of the present experiment is that hydroxy-
chloroquine induces a marked decrease in glioma cell viability
at its lowest level of each anti-cancer drug on both U87MG
and T98G cell lines in a dose-dependent manner. That is,
we can draw the conclusion that the treatment with hydro-
xychloroquine prior to anti-cancer chemotherapy maximizes
its tumoricidal effect on malignant glioma cells and reverse
chemotherapy resistance with acceptable drug toxicity.
However, this experiment is limited by the following fact;
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1) both pharmacokinetic and hemodynamic perspectives
between anti-cancer drug and anti-malaria drugs are not
taken into account. 2) Even if malignant gliomas express
mdr1, multiple or redundant mechanisms of resistance may
be present in tumor cells. 3) Inability to achieve adequate
drug concentrations in vivo that are active in vitro. 4) The
populations of cells in malignant gliomas are heterogeneous
with respect to drug sensitivity and response to reversal agents
of multi-drug resistance2). Therefore, it is important to study
local delivery of agents that modulate other mechanism of
drug resistance. Although controlled clinical studies will be
required, our results suggest that hydroxychloroquine can be
used in the chemotherapy of malignant gliomas and its po-
tential role in malignant glioma deserves clinical investigation.
Conclusion
The findings of this study demonstrate that hydroxych-loroquine induces a dramatic tumoricidal effect of
chemotherapeutic agents on malignant glioma cell lines in
vitro and may represent a significant novel therapeutic appro-
ach to malignant gliomas. 
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